Gracell announces completion of acquisition

Gracell Biotechnologies (GRCL) announced the completion of its previously announced agreement to be acquired by AstraZeneca (AZN), in accordance with the terms and conditions of the Agreement and Plan of Merger, dated as of December 23, 2023, by and among the Company, AstraZeneca Treasury Limited, a private limited company incorporated under the laws of England and Wales, and Grey Wolf Merger Sub, an exempted company with limited liability incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of Parent. The acquisition was structured as a merger of Merger Sub with and into the Company with the Company surviving the merger as a wholly owned subsidiary of Parent. As a result of the Merger, the Company ceased to be a publicly traded company and became a wholly owned subsidiary of Parent.